Skip to main
GYRE

GYRE Stock Forecast & Price Target

GYRE Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gyre Therapeutics Inc is well-positioned for growth due to its strategic acquisition of generic nintedanib, which enhances its capital base and operational capabilities during challenging market conditions. This move solidifies Gyre's leadership in the idiopathic pulmonary fibrosis (IPF) space while broadening its portfolio of therapies targeting both lung and liver fibrosis. Additionally, the company demonstrates a diverse pipeline with multiple drug candidates, including those in China, indicating a robust foundation for future revenue expansion.

Bears say

Gyre Therapeutics Inc is experiencing a negative financial outlook primarily due to depressed forward multiples attributed to current market volatility, which reflects broader concerns in the pharmaceutical sector. Additionally, the company’s reliance on commercial sales of certain drugs, such as pirfenidone in China, is undercut by the absence of growth potential, as revenue generation has plateaued. Furthermore, significant cash burn challenges are anticipated depending on the progress of development programs, which could exacerbate financial strain without reliable erratic offsetting from collaborative revenue streams.

GYRE has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gyre Therapeutics Inc (GYRE) Forecast

Analysts have given GYRE a Strong Buy based on their latest research and market trends.

According to 2 analysts, GYRE has a Strong Buy consensus rating as of Feb 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gyre Therapeutics Inc (GYRE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.